ASSESSMENT OF IMMUNOTOXICITY OF BUPRENORPHINE

被引:19
作者
VANLOVEREN, H
GIANOTTEN, N
HENDRIKSEN, CFM
SCHUURMAN, HJ
VANDERLAAN, JW
机构
[1] National Institute of Public Health and Environmental Protection, 3720 BA Bilthoven
关键词
RAT; IMMUNOTOXICOLOGY; BUPRENORPHINE; TOXICOLOGY; ANALGESIA;
D O I
10.1258/002367794780745119
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
In order to use buprenorphine as an analgesic in immunological experiments, we have studied the potential immunotoxicity of buprenorphine. Three-week-old male Wistar Riv:TOX rats were subcutaneously treated with buprenorphine by injection of 0.1, 0.4, or 1.6 mg/kg body weight per day over a period of 4 weeks. Concentrations used were within the range for analgesia in rats. A slight decrease of body weight gain was observed at the highest dose in one but not in a duplicate study. Decreased liver weights were observed in all dose groups. Histopathologically glycogen storage was decreased and fatty vacuolation was found to be increased starting from the lowest dose group. The relative but not absolute weight of the lungs was slightly increased at the lowest dose, this phenomenon was therefore not dose-dependent. Histopathologically, a dose-dependent increase in interstitial pneumonia in the lung was found. At the 2 higher dose levels the weight of the adrenal glands was increased. No haematological changes were found, nor were there effects on bone marrow. In one of 2 studies indications of potential immunotoxicity noted were: an increased weight of the thymus, as well as an increased weight of popliteal and mesenteric lymph nodes. No effects on the weight of the spleen were found. Histologically, there were no changes in the lymphoid organs tested. Total immunoglobulin A concentrations in serum were significantly decreased in the highest dose group, whereas IgG concentrations were increased, albeit not statistically significantly. IgM and IgE concentrations showed no alterations. Two types of immune function assays were carried out: determination of natural killer cell activity and of mitogen responsiveness of spleen cells. Whereas natural killer activity was unaffected, increased responses to concanavalin-A, phytohaemagglutinin, pokeweed mitogen as well as lipopolysaccharide were found, although never statistically significant. The results indicate that buprenorphine may have a slight stimulatory influence on the immune system at dose levels that are used for analgesia. The effects on the immune system that were noted were modest. Moreover, they were observed in conjunction with other toxicological effects, and can therefore either be direct or indirect.
引用
收藏
页码:355 / 363
页数:9
相关论文
共 13 条
[1]   MORPHINE-INDUCED IMMUNE ALTERATIONS INVIVO [J].
ARORA, PK ;
FRIDE, E ;
PETITTO, J ;
WAGGIE, K ;
SKOLNICK, P .
CELLULAR IMMUNOLOGY, 1990, 126 (02) :343-353
[2]  
CHAO CC, 1990, J PHARMACOL EXP THER, V252, P605
[3]   OPIOID-PEPTIDES MODULATE IMMUNE FUNCTIONS - A REVIEW [J].
FISCHER, EG .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1988, 10 (03) :265-326
[4]  
Flecknell P. A., 1991, Animals in biomedical research. Replacement, reduction and refinement: present possibilities and future prospects.., P213
[5]   THE CLINICAL USEFULNESS OF AGONIST-ANTAGONISTIC OPIOID ANALGESICS IN CHRONIC PAIN [J].
HANKS, GW .
DRUG AND ALCOHOL DEPENDENCE, 1987, 20 (04) :339-346
[6]   NATURAL-KILLER CELLS - THEIR ROLE IN DEFENSES AGAINST DISEASE [J].
HERBERMAN, RB ;
ORTALDO, JR .
SCIENCE, 1981, 214 (4516) :24-30
[7]   OPIOID-PEPTIDES MEDIATE THE SUPPRESSIVE EFFECT OF STRESS ON NATURAL-KILLER CELL CYTO-TOXICITY [J].
SHAVIT, Y ;
LEWIS, JW ;
TERMAN, GW ;
GALE, RP ;
LIEBESKIND, JC .
SCIENCE, 1984, 223 (4632) :188-190
[8]   EFFECT OF MORPHINE ON RESISTANCE TO INFECTION [J].
TUBARO, E ;
BORELLI, G ;
CROCE, C ;
CAVALLO, G ;
SANTIANGELI, C .
JOURNAL OF INFECTIOUS DISEASES, 1983, 148 (04) :656-666
[9]   METHADONE VS MORPHINE - COMPARISON OF THEIR EFFECT ON PHAGOCYTIC FUNCTIONS [J].
TUBARO, E ;
SANTIANGELI, C ;
BELOGI, L ;
BORELLI, G ;
CAVALLO, G ;
CROCE, C .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1987, 9 (01) :79-88
[10]  
VANDERLAAN JW, 1990, NEW LEADS OPIOID RES, P328